Hercules Capital, Inc. (HTGC) - Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. Hercules Capital, Inc. is an internally managed, non-diversified closed-end management investment company regulated as a Business Development Company (BDC) under the Investment Company Act of 1940. The Company focuses on providing senior secured loans to high-growth, innovative venture capital-backed and institutional-backed companies in technology and life sciences industries.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Net Investment Income | $77.5 million | $79.2 million |
| Net Increase in Net Assets (Operations) | $50.3 million | $91.0 million |
| Net Asset Value (NAV) per Share | $11.55 | $11.63 |
| Total Investments (Fair Value) | $3.92 billion | $3.66 billion |
| Total Debt Outstanding | $2.00 billion | $1.78 billion |
| Weighted Average Cost of Debt | 4.9% | 4.9% |
| Portfolio Core Yield (Non-GAAP) | 12.6% | 14.0% |
| Distributions per Share | $0.47 | $0.48 |
Material Changes vs. Prior Period
- Operating Results: Net increase in net assets from operations decreased by approximately 45% year-over-year, primarily driven by a shift from net unrealized appreciation in Q1 2024 to net unrealized depreciation of $25.6 million in Q1 2025. This depreciation was attributed to increased impairments and higher discount rates used in valuations.
- Realized Gains/Losses: The Company recorded a net realized loss of $1.6 million in Q1 2025, compared to a net realized gain of $8.2 million in Q1 2024. The loss included write-offs of equity/warrant investments and foreign exchange losses.
- Investment Income: Total investment income remained relatively flat at $119.5 million, though fee income declined to $3.9 million from $5.8 million due to lower fee accelerations from early repayments.
- Debt and Liquidity: Total debt increased by approximately $230 million to $2.00 billion, funded by the issuance of $287.5 million in 2028 Convertible Notes and increased utilization of credit facilities. Available liquidity stood at $615.6 million.
Guidance, Outlook, and Risks
- Valuation Sensitivity: The filing highlights significant sensitivity to interest rate assumptions. A hypothetical 100 basis point increase in yield rates would decrease the fair value of debt investments by approximately $52.8 million.
- Portfolio Concentration: Six portfolio companies represented greater than 5% of net assets, including Phathom Pharmaceuticals (8.8%), Marathon Health (8.7%), and Axsome Therapeutics (8.5%).
- Unfunded Commitments: The Company has $455.7 million in available unfunded commitments to portfolio companies, subject to milestones and borrowing base requirements.
- Regulatory Status: The Company maintained its status as a Regulated Investment Company (RIC) and complied with BDC asset coverage ratios (216.6% excluding SBA debentures).
- Subsequent Events: On April 23, 2025, the Board declared a distribution of $0.47 per share ($0.40 base + $0.07 supplemental) payable May 20, 2025. Additionally, the Company sold 2.2 million shares via its ATM program for $41.5 million in net proceeds.
Investor Verification Checklist
- Unrealized Depreciation Drivers: Verify the specific portfolio companies contributing to the $25.6 million net unrealized depreciation and the rationale for increased discount rates.
- Convertible Note Terms: Review the conversion price ($21.48) and settlement terms of the newly issued $287.5 million 2028 Convertible Notes.
- Non-Accrual Status: Confirm the status of the 1.8% of the portfolio on non-accrual status and any associated collateral coverage.
- PIK Interest Exposure: Assess the impact of $13.5 million in PIK interest income on cash flow requirements for distributions.
- Concentration Risk: Monitor the performance of the top six portfolio companies, which collectively represent over 40% of net assets.